The future of patient-derived xenografts in prostate cancer research.

Autor: Lawrence MG; Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia. mitchell.lawrence@monash.edu.; Melbourne Urological Research Alliance, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia. mitchell.lawrence@monash.edu.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. mitchell.lawrence@monash.edu.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. mitchell.lawrence@monash.edu.; Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia. mitchell.lawrence@monash.edu., Taylor RA; Melbourne Urological Research Alliance, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.; Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia.; Department of Physiology, Monash University, Clayton, Victoria, Australia., Cuffe GB; Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia., Ang LS; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Clark AK; Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.; Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands., Goode DL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Porter LH; Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia., Le Magnen C; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.; Department of Urology, University Hospital Basel, Basel, Switzerland.; Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland., Navone NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schalken JA; Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands., Wang Y; Vancouver Prostate Centre, Vancouver, British Columbia, Canada.; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada., van Weerden WM; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Corey E; Department of Urology, University of Washington, Seattle, WA, USA., Isaacs JT; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Pharmacology and Molecular Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Nelson PS; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Urology, University of Washington, Seattle, WA, USA., Risbridger GP; Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia. gail.risbridger@monash.edu.; Melbourne Urological Research Alliance, Monash Biomedicine Discovery Institute, Clayton, Victoria, Australia. gail.risbridger@monash.edu.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. gail.risbridger@monash.edu.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. gail.risbridger@monash.edu.; Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia. gail.risbridger@monash.edu.
Jazyk: angličtina
Zdroj: Nature reviews. Urology [Nat Rev Urol] 2023 Jun; Vol. 20 (6), pp. 371-384. Date of Electronic Publication: 2023 Jan 17.
DOI: 10.1038/s41585-022-00706-x
Abstrakt: Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few prostate cancer PDXs are available in large repositories, over 330 prostate cancer PDXs have been established, spanning broad clinical stages, genotypes and phenotypes. Nevertheless, more PDXs are needed to reflect patient diversity, and to study new treatments and emerging mechanisms of resistance. We can maximize the use of PDXs by exchanging models and datasets, and by depositing PDXs into biorepositories, but we must address the impediments to accessing PDXs, such as institutional, ethical and legal agreements. Through collaboration, researchers will gain greater access to PDXs representing diverse features of prostate cancer.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: